{"transactions":[{"id":946628,"issuer":{"id":5028,"kind":"organization","name":"Silence Therapeutics plc"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2026-01-06T21:15:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date."}],"balance_after":375000,"derivative":{"exercise_price":2.05,"expiration_date":"2036-01-02","underlying":"Ordinary Shares","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001766456-26-000002","document":"form4-01062026_040103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479615/000176645626000002/form4-01062026_040103.xml","form_type":"4"}},{"id":1310492,"issuer":{"id":5028,"kind":"organization","name":"Silence Therapeutics plc"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2025-01-06T21:15:08.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date."}],"balance_after":375000,"derivative":{"exercise_price":2.4,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001415889-25-000744","document":"form4-01062025_040104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479615/000141588925000744/form4-01062025_040104.xml","form_type":"4"}},{"id":3459015,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":67527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":4.44,"underlying":"Common Stock","underlying_shares":67527},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459014,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":15100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":4.22,"underlying":"Common Stock","underlying_shares":15100},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459013,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":14700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":4.83,"underlying":"Common Stock","underlying_shares":14700},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459012,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":4100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":8.02,"underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459011,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":6700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":3.14,"underlying":"Common Stock","underlying_shares":6700},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459010,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":2650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":17.18,"underlying":"Common Stock","underlying_shares":2650},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459009,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares."}],"balance_after":0,"derivative":{"exercise_price":22.91,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3459008,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2019-07-18T19:45:36.000Z","date":"2019-07-18","kind":"disposition_to_issuer","acquired":false,"shares":51424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the \"Merger Agreement\") among Aratana Therapeutics, Inc. (the \"Company\"), Elanco Animal Health Incorporated (\"Elanco\") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco (\"Elanco Athens\"), Elanco Athens merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the \"Stock Consideration\"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the \"Merger Consideration\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the \"Merger Agreement\") among Aratana Therapeutics, Inc. (the \"Company\"), Elanco Animal Health Incorporated (\"Elanco\") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco (\"Elanco Athens\"), Elanco Athens merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the \"Stock Consideration\"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-042719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119042719/doc4.xml","form_type":"4"}},{"id":3673655,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T17:48:12.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":67527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on February 1, 2020 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on February 1, 2023, subject to continued service with the Issuer through the applicable vesting dates."}],"balance_after":67527,"derivative":{"exercise_price":4.44,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":67527},"source":{"system":"sec-edgar","filing":"0001209191-19-007450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119007450/doc4.xml","form_type":"4"}},{"id":3673654,"issuer":{"id":155913,"kind":"organization","name":"ARATANA THERAPEUTICS, INC.","symbol":"PETX"},"owners":[{"id":69997,"kind":"person","name":"HELLUMS RHONDA LYNETTE","position":1,"cik":"0001766456","reported_name":"HELLUMS RHONDA LYNETTE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2019-02-05T17:48:12.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":24923,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51424,"source":{"system":"sec-edgar","filing":"0001209191-19-007450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509190/000120919119007450/doc4.xml","form_type":"4"}}]}